FDA Commissioner Marty Makary's vision for the agency risks the best of an agency that mostly has functioned well for the ...

Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide TherapyTM (PRnT) solutions, today announced the submission of ...

HistoSonics, the manufacturer of the Edison® Histotripsy System, today announced that Highmark Blue Cross Blue Shield has ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

New investment to accelerate pivotal PARADIGM Trial progress, FDA regulatory pathway, upper GI early feasibility studies, and ...

Ultragenyx received a Complete Response Letter from the FDA for UX111 AAV gene therapy to treat Sanfilippo Syndrome Type A ...

Zimmer Biomet (NYSE: ZBH) announced today that it entered into a definitive agreement to acquire Monogram Technologies ...

A New Jersey based company is recalling its 200 g packages of needle mushrooms because they may be contaminated with listeria ...

The FDA cited manufacturing issues but did not flag problems with Ultragenyx’s data package for UX111, with the biotech ...

Through its recently unveiled Priority Voucher program, the FDA seeks to accelerate the review process for companies that ...

A new report from a key Senate committee expresses concerns about “misleading” marketing of cannabis products and notes the ...

Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.